Evidence map›Paper›PMID 28025702›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2017

Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.

Mariko Kiso, Masaharu Yoshihara, Masanori Ito, Kazuhiko Inoue, Katsuaki Kato, Shigemi Nakajima, Katsuhiro Mabe, Masao Kobayashi, Naomi Uemura, Tomoyuki Yada and 7 more

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Prevalence ofFrontiers in oncology · 2022
    Pooled it
  3. Article
  4. Endoscopic differential diagnosis between foveolar-type gastric adenoma and gastric hyperplastic polyps in Helicobacter pylori-naïve patients.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
  5. Article
  6. Gastric Cancer Screening in Japan: A Narrative Review.Journal of clinical medicine · 2022
    Review
  7. Article
  8. Intestinal-type gastric dysplasia in Helicobacter pylori-naïve patients.Virchows Archiv : an international journal of pathology · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Classifying risk level of gastric cancer: Evaluation of questionnaire-based prediction model.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020
    Article
  16. Article
  17. Article
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Mariko KisoDepartment of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
Masaharu YoshiharaHealth Service Center, Hiroshima University, Higashi-Hiroshima, Japan. myoshih@hiroshima-u.ac.jp.
Masanori ItoDepartment of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
Kazuhiko InoueDepartment of General Medicine, Kawasaki Medical School, Kurashiki, Japan.
Katsuaki KatoDepartment of Cancer Detection Center, Miyagi Cancer Society, Sendai, Japan.
Shigemi NakajimaDepartment of General Medicine, Gastroenterology and Health-care, Japan Community Health-care Organization Shiga Hospital, Otsu, Japan.
Katsuhiro MabeDepartment of Gastroenterology, National Hospital Organization Hakodate Hospital/Cancer Preventive Medicine, Hokkaido University, Sapporo, Japan.
Masao KobayashiDepartment of Health Care Division, Kyoto Second Red Cross Hospital, Kyoto, Japan.
Naomi UemuraDepartment of Gastroenterology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.
Tomoyuki YadaDepartment of Gastroenterology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.
Masashi OkaDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Kawagoe, Japan.
Takashi KawaiDepartment of Endoscopy Center, Tokyo Medical University Hospital, Tokyo, Japan.
Tomoyuki BodaDepartment of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan.
Takahiro KotachiDepartment of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
Kazuhiko MasudaDepartment of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
Shinji TanakaDepartment of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
Hiroshima University · JPHiroshima University Hospital · JPNational Center for Global Health and Medicine · JPJapan Cancer Society · JPJapan Community Healthcare Organization · JPKawasaki Medical School · JPKyoto first Red Cross hospital · JPNational Hospital Organization · JPSaitama Medical University · JPTokyo Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe serological risk prediction system combines the pepsinogen test and anti-Helicobacter pylori (H. pylori) antibody determination. In this system, chronic atrophic gastritis (CAG) is diagnosed using the pepsinogen test. Patients who are H. pylori negative and pepsinogen negative are classified into group A, are assumed to be H. pylori uninfected, and are at an extremely low risk for gastric cancer. However, gastric cancers are detected in this group. The aim of this study is to clarify the clinicopathological status of group A patients with gastric cancer.

methodsA total of 109 gastric cancer patients classified as group A were enrolled in a multicenter study. Group A patients were divided into two subgroups: group AN (H. pylori uninfected) and group AP (H. pylori infected). They were compared to 183 H. pylori-infected gastric cancer patients who were not in group A.

resultsOf the 109 patients, only 7 were classified as group AN; the other 102 were classified as group AP. The clinicopathological features of group AP included older age, predominantly differentiated type cancer, endoscopically visualized CAG, and pepsinogen (PG) I/II ratio lower than that of group AN. In group AN, the depressed type was dominant, and the PG I/II ratio was higher than in those gastric cancer patients who were infected with H. pylori.

conclusionPatients in group AP had CAG, and their gastric cancers were similar to those of H. pylori-eradicated patients. Concerning the recent ABC classification system, advanced decision criteria should be proposed to decrease the false-negative evaluation of gastric cancer risk.

Indexed as

AdultAgedAged, 80 and overAge FactorsAntibodies, BacterialFalse Negative ReactionsFemaleGastritis, AtrophicHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPepsinogen ARisk FactorsStomach NeoplasmsAntibodies, BacterialPepsinogen AGastric cancerGastritisHelicobacter pyloriPepsinogenSerological risk prediction system

Identifiers

PMID28025702
OpenAlexW2565337441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.